Big Molecule Watch

APRIL 29, 2024

patents directed to mRNA vaccine technology. 1 variant vaccine; (3) the bivalent Comirnaty® COVID-19 original plus BA.4/5 4/5 variant vaccine; and (4) the monovalent Comirnaty® COVID-19 XBB.1.5 variant vaccine.” infringe five U.S. The Patents-In-Suit are U.S. Patent Nos.

Vaccines 53

Vaccines 53

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. This is in addition to its long-available pneumococcal polysaccharide vaccine PPSV23.

Vaccines 64

Vaccines Immunity Immunization 64

pharmaphorum

APRIL 7, 2021

Jan van de Winkel has overseen one of biotech’s big success stories since he took over Genmab’s CEO in 2010. It has brought a lot of good things working together and networking has led to unbelievable successes,” he added, noting the rapid development of vaccines by companies such as Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University.

Chemotherapy 91

Chemotherapy Hospitals Vaccines 91

European Pharmaceutical Review

SEPTEMBER 18, 2023

Events, as well as talks from industry leaders and networking opportunities, will be coordinated by a new ‘Scottish Advanced Therapy Medicinal Products (ATMP) and Vaccines Network’ to aid individuals and the wider industry across the north of the UK. Since 2010, the sector has secured eight percent growth each year.

Vaccines 117

Vaccines 117

pharmaphorum

SEPTEMBER 18, 2020

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 Its oncology treatment Arimidex lost exclusivity in the US in 2009, accounting for a sales decrease of 86%, as published in the 2010 annual report. Pascal Soriot.

Vaccines 116

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 116

pharmaphorum

OCTOBER 26, 2020

Strategies include different options focused on health maintenance, such as vaccination programmes, smoking cessation services, support for physical activity, and access to technologies that support early detection of diseases. Figure 1: OECD average of public spending on health (Source: OECD ). per person in the US) and is widely adopted.

Vaccines 130

Vaccines 130

European Pharmaceutical Review

JANUARY 31, 2023

billion in poorer countries access to full medicine portfolio… MPP has signed 34 licences for various health technologies and facilitated access to 30 billion doses of treatments since 2010. NEWS: Pfizer offers 1.2 These successes have helped to define its new strategy.

Communication 105

Communication Vaccines 105

pharmaphorum

SEPTEMBER 8, 2020

When the day hopefully comes where a vaccine is widely available, we will be relieved of the great stress and uncertainty of this time. 4 Global oncology spending in 2010, 2015, and 2020, by region (in billion U.S. Available from : [link] [Last accessed: September 2020]. 3 Wilking N, Lopes G, Meier K, et al. Touch Oncology.

Biosimilars 99

Biosimilars Drug Pricing Chemotherapy Vaccines 99

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Hospitals 105

Hospitals Pharmaceutical Companies Pharmaceutical Companies Vaccines 105

pharmaphorum

JANUARY 27, 2023

The recent reversal of China’s “zero Covid” policy, at a time when the country still lacks optimal vaccine coverage, has also created another unknown, in terms of global supply and demand forecasting. He previously held regional leadership roles at Sandoz between 2005 and 2010.

Packaging 105

Packaging Biosimilars Vaccines 105

European Pharmaceutical Review

MARCH 11, 2024

For example, rising ambient temperatures and ingress of mould from items entering cleanrooms, has resulted in some vaccine and pharmaceutical companies in Europe experiencing increased contamination. Ahmed et al.

Sterile Compounds 98

Sterile Compounds Compounding Packaging Pharmaceutical Companies 98

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Mayo Clinic 98

Mayo Clinic Hospitals Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

FEBRUARY 23, 2023

His prior appointments include senior global R&D, and quality leadership roles across diverse drug, device and biologics portfolios for the likes of Baxter Healthcare, Eli Lilly and Evans Vaccines. Edward actively publishes and is a leading authority on pharmaceutical microbiology, risk, aseptic and sterile manufacturing.

Dosage 111

Dosage Vaccines 111

pharmaphorum

MARCH 2, 2021

The Conservative Party has strong ties with pharma and life sciences and has been backing the industry since David Cameron led it back to power in 2010 with a range of policies aimed at boosting research and investment. billion investment in equity finance in the sector in 2020.

Vaccines 105

Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

European Pharmaceutical Review

DECEMBER 26, 2023

Single-use bioprocessing technologies enabling more rapid vaccines production [Internet]. Available from: [link] About the author Kai Lipinski, PhD joined Vibalogics, now ReciBioPharm, in 2010 as Head of Cell Culture and Virus Production. Available from: [link] Nielsen J, Tillegreen CB, Petranovic D. Trends in Biotechnology.

Drug Pricing 98

Drug Pricing Packaging Vaccines Drug Development 98

pharmaphorum

OCTOBER 12, 2022

Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines. Just as mRNA and COVID-19 showed the world that it’s possible to develop vaccines much faster, Del Bourgo explains, AI can help us develop new genomic medicines in a more efficient way.

Drug Development 105

Drug Development Immunity Immunization Vaccines 105

pharmaphorum

JANUARY 19, 2023

Waiting lists have grown not because of COVID, but [have been] growing consistently since 2010.” The vaccine programme is the best example,” Lord Prior said. BioNTech, or Pfizer, or others – within nine months, we had a vaccine, ran clinical trials at scale, cheaply and quickly.” It’s our last throw,” Lord Prior explained.

Hospitals 96

Hospitals Vaccines 96

pharmaphorum

OCTOBER 24, 2022

Exemptions include exceptional central procurements, centrally procured vaccines, small company sales, and low-value sales (when the NHS list price is less than £2). It’s been around for some time, having first been introduced in 2010 on a regional basis. As ever, the controversy is about the trade-offs and just where to draw the line.

Vaccines 75

Vaccines 75

pharmaphorum

OCTOBER 12, 2021

billion in 2010. At the moment there’s no world on a possible replacement for Stoffels, who oversees the pharma industry’s third-largest R&D budget at more than $12 billion in 2020, up from $6.8

Vaccines 52

Vaccines 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 64

Pharmaceutical Companies Pharmaceutical Companies Vaccines 64

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Vaccines 98

Vaccines Pharmaceutical Companies Pharmaceutical Companies Hospitals 98

pharmaphorum

APRIL 4, 2022

Until now, AXA Investment Managers has been focused more on the delivery end of health care – health centres and private hospitals, for example – but the new strategy is directed at four key areas, including biopharma, vaccines, medical devices and diagnostics companies.

Vaccines 59

Vaccines Hospitals 59

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Vaccines 96

Vaccines Immunity Immunization Pharmaceutical Companies 96

PharmaShots

FEBRUARY 21, 2023

Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines. Under its radiopharmaceutical segment, OncoTherapy is developing OTSA101, an anti-FZD10 antibody that specifically binds to FZD10 in cancer cells.

Dosage 56

Dosage Labelling Immunity Immunization 56

Pharmaceutical Technology

JULY 21, 2022

In 2010, only eight big pharma companies had an access strategy for low- and middle-income countries, but today, 17 of the biggest 20 companies do. According to the World Health Organization (WHO), two billion people lack access to essential or basic drugs. Drug pricing and gouging.

Drug Pricing 52

Drug Pricing Vaccines 52

Pharmaceutical Technology

MAY 15, 2023

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Adverse Reactions 52

Adverse Reactions Mayo Clinic Immunity Immunization 52

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Mayo Clinic 52

Mayo Clinic Hospitals Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

APRIL 18, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Compounding 52

Compounding Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

APRIL 18, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Hospitals 52

Hospitals Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Immunity 52

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Mayo Clinic 52

Mayo Clinic Hospitals Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Immunity 52

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

MAY 24, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Diabetes 52

Diabetes Hospitals Immunity Immunization 52